^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
CANCER:

Gastroesophageal Cancer

Related cancers:
HER-2 positive
Gastroesophageal Cancer
trastuzumab
Sensitive
:
A2
PD-L1 overexpression
Gastroesophageal Cancer
PD1 inhibitor
Sensitive
:
B
PD-L1 overexpression
Gastroesophageal Cancer
PD-L1 inhibitor
Sensitive
:
B
HER-2 amplification
Gastroesophageal Cancer
trastuzumab
Sensitive
:
B
PD-L1 expression
Gastroesophageal Cancer
pembrolizumab
Sensitive
:
C1
HER-2 positive
Gastroesophageal Cancer
pembrolizumab + trastuzumab
Sensitive
:
C1
HER-2 positive
Gastroesophageal Cancer
pembrolizumab
Sensitive
:
C2
TP53 mutation
Gastroesophageal Cancer
Immunotherapy
Resistant
:
C3
TET1 mutation
Gastroesophageal Cancer
Immunotherapy
Sensitive
:
C3
HER-2 expression
Gastroesophageal Cancer
ZW25
Sensitive
:
C3
PD-L1 expression
Gastroesophageal Cancer
Immunotherapy
Sensitive
:
C3
HER-2 overexpression
Gastroesophageal Cancer
disitamab vedotin
Sensitive
:
C3
PD-L1 expression
Gastroesophageal Cancer
tislelizumab
Sensitive
:
C3
FGFR2 amplification
Gastroesophageal Cancer
ABSK091
Sensitive
:
C3
MET amplification
Gastroesophageal Cancer
crizotinib
Sensitive
:
C3
TGFB1 elevation
Gastroesophageal Cancer
M7824
Sensitive
:
C3
HER-2 overexpression
Gastroesophageal Cancer
ZW25
Sensitive
:
C3
MET amplification
Gastroesophageal Cancer
afatinib
Resistant
:
C3
EGFR amplification + ERBB2 amplification
Gastroesophageal Cancer
afatinib
Sensitive
:
C3
CFB overexpression
Gastroesophageal Cancer
sunitinib
Sensitive
:
C3
VEGFC-H
Gastroesophageal Cancer
sunitinib
Sensitive
:
C3
HER-2 positive
Gastroesophageal Cancer
pembrolizumab + margetuximab
Sensitive
:
C3
POLE mutation
Gastroesophageal Cancer
Immunotherapy
Sensitive
:
C3
POLD1 mutation
Gastroesophageal Cancer
Immunotherapy
Sensitive
:
C3
PD-L1 expression
Gastroesophageal Cancer
PD-L1 inhibitor
Sensitive
:
C3
PD-L1 expression
Gastroesophageal Cancer
PD1 inhibitor
Sensitive
:
C3
HER-2 positive + HER-2 amplification
Gastroesophageal Cancer
trastuzumab
Sensitive
:
C3
CTAG1A expression
Gastroesophageal Cancer
Immunotherapy
Sensitive
:
C3
HER-2 positive + PD-L1 expression
Gastroesophageal Cancer
margetuximab + retifanlimab
Sensitive
:
C3
HER-2 mutation
Gastroesophageal Cancer
dasatinib
Sensitive
:
D
HER-2 mutation
Gastroesophageal Cancer
neratinib
Sensitive
:
D
HER-2 mutation
Gastroesophageal Cancer
dasatinib + neratinib
Sensitive
:
D